[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Lee S, Park YH, Kim KH, Cho EY, Ahn YC, Kim K, Shim YM, Ahn JS, Park K, Im YH: Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma. Br J Cancer; 2010 Sep 7;103(6):845-51
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma.
  • BACKGROUND: Our purpose was to evaluate thymidine synthase (TS), thymidine phosphorylase (TP), and excision repair cross-complementation group 1 (ERCC1) expression as biomarkers for capecitabine and cisplatin (XP) combination chemotherapy in patients with metastatic oesophageal squamous cell cancer.
  • METHOD: A total of 113 patients with metastatic oesophageal squamous cell cancer were treated with XP chemotherapy at the Samsung Medical Center between 2003 and 2007, of whom 72 had available clinical data and paraffin blocks for immunohistochemistry of TS, TP, and ERCC1.
  • High expression of TS and TP was associated with a higher RR than was low expression of TS and TP (54.1 vs 40.5%, P=0.022).
  • CONCLUSION: These data indicate that expression of TS, TP, and ERCC1 may be predictive markers for response and survival in patients with metastatic oesophageal squamous cell cancer receiving XP chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. DNA-Binding Proteins / metabolism. Endonucleases / metabolism. Esophageal Neoplasms / drug therapy. Thymidine Phosphorylase / metabolism. Thymidylate Synthase / metabolism
  • [MeSH-minor] Adult. Aged. Capecitabine. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Metastasis. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 15):12-20 [10566606.001]
  • [Cites] Br J Cancer. 2010 Feb 2;102(3):475-81 [20068567.001]
  • [Cites] J Clin Oncol. 2001 Dec 1;19(23):4298-304 [11731512.001]
  • [Cites] Int J Cancer. 2002 Feb 1;97(4):512-7 [11802215.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1721-8 [11919227.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1735-43 [11919229.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):1996-2004 [11956258.001]
  • [Cites] Clin Breast Cancer. 2002 Apr;3(1):55-64 [12020396.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):241-50 [12525515.001]
  • [Cites] Histol Histopathol. 2004 Jan;19(1):129-36 [14702180.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):529-36 [14752076.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3794-9 [15173087.001]
  • [Cites] Jpn J Clin Oncol. 1992 Jun;22(3):172-6 [1518165.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):3813-8 [8508349.001]
  • [Cites] Cancer Res. 1995 Apr 1;55(7):1407-12 [7882343.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):176-82 [8558194.001]
  • [Cites] Eur J Cancer. 1997 Jul;33(8):1216-20 [9301445.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1243-50 [9607583.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2215-21 [15788669.001]
  • [Cites] Pharmacogenomics. 2005 Dec;6(8):835-47 [16296946.001]
  • [Cites] J Clin Oncol. 2006 May 10;24(14):2137-50 [16682732.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4069-77 [16943524.001]
  • [Cites] N Engl J Med. 2006 Sep 7;355(10):983-91 [16957145.001]
  • [Cites] Oncology. 2006;70(5):366-77 [17179731.001]
  • [Cites] N Engl J Med. 2008 Jan 3;358(1):36-46 [18172173.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Jun;62(1):77-84 [17762932.001]
  • [Cites] Br J Cancer. 2008 Jul 8;99(1):167-72 [18594541.001]
  • [Cites] Clin Cancer Res. 2008 Jul 1;14(13):4225-31 [18594004.001]
  • [Cites] Ann Oncol. 2009 Apr;20(4):666-73 [19153121.001]
  • [Cites] Med Res Rev. 2009 Nov;29(6):903-53 [19434693.001]
  • [Cites] Oncologist. 2001;6 Suppl 4:1-2 [11585967.001]
  • (PMID = 20700125.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; EC 2.1.1.45 / Thymidylate Synthase; EC 2.4.2.4 / Thymidine Phosphorylase; EC 3.1.- / ERCC1 protein, human; EC 3.1.- / Endonucleases; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2966625
  •  go-up   go-down


2. Takahashi H, Arimura Y, Yamashita K, Okahara S, Tanuma T, Kodaira J, Hokari K, Tsukagoshi H, Shinomura Y, Hosokawa M: Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma. J Thorac Oncol; 2010 Jan;5(1):122-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma.
  • INTRODUCTION: More effective regimens are urgently needed for squamous cell carcinoma of esophagus (SCCE), therefore, we conducted a phase I/II trial of a combination of docetaxel, platinum, and fluorouracil (TPF) for treating metastatic SCCE.
  • RESULTS: The recommended dose of docetaxel was determined to be 50 mg/m in phase I.
  • In phase II with a mean follow-up period of 13.3 months, the objective response rate was 66.6%, a median survival period of 13 months and PFS of 7 months was achieved, and the 1-year survival and PFS rates were 52.9% and 19.6%, respectively.
  • CONCLUSIONS: A TPF regimen against metastatic SCCE was well tolerated and achieved a favorable objective response rate and survival benefit compared with other recently reported regimens.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Esophageal Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Taxoids / administration & dosage. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19898259.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


3. Tougeron D, Di Fiore F, Thureau S, Berbera N, Iwanicki-Caron I, Hamidou H, Paillot B, Michel P: Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer. Br J Cancer; 2008 Nov 18;99(10):1586-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer.
  • Little is known about chemoradiotherapy (CRT) in elderly patients with a locally advanced oesophageal cancer (OC).
  • The aim of our study was to evaluate the tolerance and the outcome of elderly patients older than 70 years treated with CRT for a non-metastatic OC.
  • Chemoradiotherapy was based on radiotherapy combined with a cisplatin-based chemotherapy.
  • Clinical complete response (CCR) to CRT was evaluated on upper digestive endoscopy and computed tomography scan 6-8 weeks after CRT completion.
  • Chemotherapy dose reduction, chemotherapy delays more than 1 week, and treatment discontinuation were observed in 33 (30.3%), 45 (41.3%), and 17 patients (15.6%), respectively.
  • Comorbidity index according to Charlson score was significantly associated with treatment tolerance.
  • These results suggest that CRT could be considered as an effective treatment without major toxicity in elderly patients with OC.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Agents / administration & dosage. Carcinoma, Squamous Cell / therapy. Cisplatin / administration & dosage. Esophageal Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Strahlenther Onkol. 2007 Jan;183(1):30-5 [17225943.001]
  • [Cites] Ann Thorac Surg. 2006 Dec;82(6):2031-6; discussion 2036 [17126106.001]
  • [Cites] J Thorac Cardiovasc Surg. 2007 May;133(5):1186-92 [17467427.001]
  • [Cites] Eur J Cancer. 2007 Jun;43(9):1445-51 [17512189.001]
  • [Cites] J Clin Oncol. 2007 Jun 10;25(17):2389-96 [17557952.001]
  • [Cites] Br J Cancer. 2007 Jun 18;96(12):1823-7 [17533399.001]
  • [Cites] Eur J Cardiothorac Surg. 2007 Sep;32(3):445-8 [17643999.001]
  • [Cites] J Clin Oncol. 2007 Sep 10;25(26):4110-7 [17827461.001]
  • [Cites] Ann Surg Oncol. 2007 Nov;14(11):3243-50 [17713823.001]
  • [Cites] Am J Clin Oncol. 2007 Dec;30(6):607-11 [18091055.001]
  • [Cites] Ann Oncol. 2008 May;19 Suppl 2:ii21-2 [18456754.001]
  • [Cites] Gastroenterol Clin Biol. 2008 Mar;32(3):213-20 [18372134.001]
  • [Cites] Eur J Cardiothorac Surg. 2008 Jun;33(6):1096-104 [18407509.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2412-8 [10561304.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2915-21 [10561371.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):455-62 [10653860.001]
  • [Cites] Ann Surg Oncol. 2002 Mar;9(2):210-4 [11888881.001]
  • [Cites] Oncology. 2007;73(5-6):328-34 [18497505.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • [Cites] Rev Epidemiol Sante Publique. 2003 Feb;51(1 Pt 1):3-30 [12684578.001]
  • [Cites] Gastroenterol Clin Biol. 2000 Feb;24(2):201-10 [12687962.001]
  • [Cites] Br J Cancer. 2003 Dec 1;89(11):2045-50 [14647136.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Feb;130(2):161-6 [14967744.001]
  • [Cites] Ann Surg. 2004 Nov;240(5):791-800 [15492560.001]
  • [Cites] Br Med J. 1977 Jan 8;1(6053):91-3 [832026.001]
  • [Cites] Hepatogastroenterology. 1990 Aug;37(4):376-81 [2210603.001]
  • [Cites] N Engl J Med. 1992 Jun 11;326(24):1593-8 [1584260.001]
  • [Cites] Eur J Cardiothorac Surg. 1996;10(11):941-6 [8971504.001]
  • [Cites] N Engl J Med. 1997 Jul 17;337(3):161-7 [9219702.001]
  • [Cites] Ann Surg. 1998 Mar;227(3):357-64 [9527058.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Feb 1;43(3):517-23 [10078631.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2310-7 [15800321.001]
  • [Cites] Aliment Pharmacol Ther. 2005 Aug 1;22(3):233-41 [16091061.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2365-72 [16245310.001]
  • [Cites] Eur J Cancer. 2006 May;42(7):827-34 [16466913.001]
  • [Cites] World J Gastroenterol. 2006 Jul 14;12(26):4185-90 [16830371.001]
  • [Cites] Gastroenterol Clin Biol. 2006 Jun-Jul;30(6-7):845-51 [16885868.001]
  • [Cites] Br J Cancer. 2006 Sep 18;95(6):705-9 [16967056.001]
  • [Cites] Anticancer Res. 2006 Sep-Oct;26(5B):3913-23 [17094422.001]
  • [Cites] J Clin Oncol. 2007 Apr 1;25(10):1160-8 [17401004.001]
  • (PMID = 19002180.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2584940
  •  go-up   go-down


Advertisement
4. Duffour J, Bouché O, Rougier P, Milan C, Bedenne L, Seitz JF, Buecher B, Legoux JL, Ducreux M, Vetter D, Raoul JL, François E, Ychou M: Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial). Anticancer Res; 2006 Sep-Oct;26(5B):3877-83
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial).
  • BACKGROUND: The objective of this phase III study was to compare the safety and efficacy of FLP (modulation of 5-FU (Fluorouracil) by folinic acid or leucovorin (LV) and cisplatin vs. FP (5-FU combined with Cisplatin) as a first line chemotherapy in advanced oesophageal, gastric and pancreatic cancer.
  • PATIENTS AND METHODS: 232 patients with measurable lesions were randomised to receive at the first cycle either FP (arm A: 5-FU 800 mg/m2/d in continuous infusion 5 days and cisplatin 100 mg/m2 on day 1 or 2), or FLP (arm B: LV, 100 mg/m2/d in bolus 5 days, followed by 5-FU 350 mg/m2/d in 1 h infusion 5 days and cisplatin 100 mg/m2 on day 1 or 2).
  • In case of no grade 3-4 haematological and diarrhoea toxicity, the dose of 5-FU was increased to 1000 mg/m2/d and 400 mg/m2/d in the two arms respectively, for the subsequent cycles until disease progression.
  • RESULTS: The distribution of primary tumours was: 19 squamous cell carcinoma of the oesophagus, 19 oesophageal adenocarcinoma, 91 gastric and 97 pancreatic adenocarcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrointestinal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Metastatic cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17094417.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


5. Farzad M, De Luca MC, Rubino G, Pirtoli L, Pepi F, Sebaste L, Ponticelli P, Atzeni G, Maranzano E, Silvano G: [Effort to radically cure stage III and IV esophageal carcinoma with simultaneous radiotherapy and chemotherapy in standard clinical practice]. Radiol Med; 2001 Jul-Aug;102(1-2):72-7
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effort to radically cure stage III and IV esophageal carcinoma with simultaneous radiotherapy and chemotherapy in standard clinical practice].
  • [Transliterated title] L'intento di cura radicale del carcinoma esofageo al III e IV stadio con radioterapia e chemioterapia concomitanti nella pratica clinica comune.
  • PURPOSE: Chemotherapy and concurrent irradiation, intended to cure, are presently standard treatments for non metastatic, unresectable oesophageal cancer.
  • The results of the combined therapy are superior to those of radiotherapy alone, attaining 25-35% 2-year survival rates.
  • However these results mainly refer to stage I and II tumours as most of the available literature has focussed on these groups.
  • The aim of our report is to present our experience with Stage III and IV patients.
  • MATERIAL AND METHODS: Sixty-four Stage III and IV oesophageal cancer patients were referred to our Departments from January 1, 1990 to December 31, 1996.
  • Diagnosis was obtained through oesophagoscopy and biopsy, stage was assessed by physical examination, chest CT scan, bronchoscopy, barium X-ray examination, upper abdomen ultrasonography and bone nuclide scan.
  • The case features were as follows: histology of squamous cell carcinoma in 32 cases, of adenocarcinoma in 2; tumour in the upper third of the oesophagus in 11 (32.5%), in the middle third in 18 (53%), in the lower third in 5 (14.5%); male/female ratio 29/5, age 48-68 years (mean 56), Karnofsky performance status of 60% or higher.
  • Twenty-one had Stage III (61.75%) and 13 stage IV (38.25%) cancer, with metastasis limited to the supraclavicular or coeliac nodes, which could be included in the radiation volume.
  • In all cases chemotherapy consisted of 5-Fluoruracil (administered in a continuous i.v. infusion, from day 1 to 5, with a 750-1.000 mg/n.sq daily dose) and Cisplatin (75-100 mg/n.sq on the first day, or 20 mg/n.sq for 5 consecutive daily doses, administered by i.v. bolus).
  • Irradiation started with the first cycle of chemotherapy in 5 patients, with the second or third cycle in 29.
  • At least two cycles of chemotherapy were administered during the course of radiation.
  • Radiotherapy was performed with 4 to 18 MeV linear accelerator X-rays, or telecobalt, through opposite anterior and posterior treatment portals or more complex field arrangements.
  • The doses were in the range of 44-66 Gy, with fractionation of 5x180-200 cGy weekly sessions.
  • After treatment, periodic follow-up controls were carried out in all cases.
  • Data on improvement of swallowing were always available, however, and the early therapeutic results were analysed accordingly.
  • Two-year survival after conclusion of the treatment was calculated according to Kaplan and Maier.
  • Survival was analysed (log-rank test) according to stage, Performance Status, oesophagectomy and body weight loss.
  • RESULTS: After treatment, subjective symptomatic relief occurred in 17 of the 22 patients presenting dysphagia (77.5%).
  • Acute toxicity (Grade III or IV WHO) of the treatment accounted for 47% of hematologic adverse effects, 40% of mucositis, 20.5% of vomiting or diarrhoea not responding to drug treatment.
  • Treatment delays of more than one week, due to toxicity, occurred in 23.5%.
  • Overall 2 year survival was 13%, with a median value of 10 months.
  • Survival analysis, according to stage, showed 2 year values of 24% in Stage III and 0% in Stage IV (p=0.09).
  • Six patients showed a remarkable improvement in symptoms and general conditions after treatment, and were restaged with oesophagoscopy, thoracic CT scan and bronchoscopy, which evidenced resectable residual tumors, and they were then operated.
  • DISCUSSION AND CONCLUSIONS: Many Stage III and IV patients, selected for an aggressive chemo-radiation approach on the grounds of satisfactory medical conditions, can obtain relief of dysphagia.
  • Some cases, without extrathoracic spread of the tumor can achieve long term survival (in our experience 24% 2-year survival in Stage III, in our experience which favourably compares with the results obtained by other authors).
  • Whether surgery may improve the therapeutic results of chemo-radiotherapy in patients whose tumour has become resectable, is an issue that cannot be satisfactorily addressed on the basis of our experience, nor are the results from the available literature exhaustive to this regard.
  • [MeSH-major] Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11677442.001).
  • [ISSN] 0033-8362
  • [Journal-full-title] La Radiologia medica
  • [ISO-abbreviation] Radiol Med
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


6. Jackson C, Starling N, Chua YJ, Cunningham D: Pharmacotherapy for oesophagogastric cancer. Drugs; 2007;67(17):2539-56
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacotherapy for oesophagogastric cancer.
  • Gastric cancer is the seventh and oesophageal cancer the ninth most common cancer in the UK, and >50% of patients present with locally advanced or metastatic disease.
  • The incidence of oesophageal and oesophagogastric junctional tumours is increasing, making these important disease entities to understand and research.
  • Outcomes in localised oesophageal cancer are improved with pre-operative chemotherapy, and in gastric cancer with peri-operative treatment or post-operative chemoradiotherapy.
  • Oesophageal squamous cell carcinoma can be treated with definitive chemoradiotherapy as an alternative to surgery.
  • While survival in patients presenting with metastatic disease is improved with the addition of systemic chemotherapy, median survival remains <1 year.
  • Patients who are otherwise fit can be offered chemotherapy and this is superior to best supportive care.
  • No standard second-line therapy has emerged.
  • New research into taxanes has shown promising anti-cancer activity, and novel areas of investigation include incorporation of agents targeting vascular endothelial growth factor or epidermal growth factor receptor into standard regimens.
  • This review focuses on the clinical trial evidence that dictates the optimal management of localised and advanced oesophagogastric cancer, focusing on pharmacotherapy.
  • We examine areas of current research and highlight future therapeutic directions.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophageal Neoplasms / therapy. Neoplasm Recurrence, Local / therapy. Stomach Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Clinical Trials as Topic. Disease Progression. Humans. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1993 Mar 1;71(5):1726-30 [8448736.001]
  • [Cites] Invest New Drugs. 2004 Jan;22(1):91-7 [14707499.001]
  • [Cites] Eur J Cancer Clin Oncol. 1985 Nov;21(11):1321-4 [4076293.001]
  • [Cites] Ann Oncol. 2004 Jun;15(6):955-9 [15151954.001]
  • [Cites] N Engl J Med. 1996 Aug 15;335(7):462-7 [8672151.001]
  • [Cites] Ann Oncol. 2000 Jul;11(7):837-43 [10997811.001]
  • [Cites] Endoscopy. 2003 Mar;35(3):207-11 [12584638.001]
  • [Cites] Br J Cancer. 2006 Dec 18;95(12):1642-7 [17133268.001]
  • [Cites] Ann Oncol. 2004 Jun;15(6):947-54 [15151953.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2903-9 [16782930.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4991-7 [17075117.001]
  • [Cites] Ann Oncol. 2004 Jan;15(1):64-9 [14679122.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):663-7 [16446338.001]
  • [Cites] Cochrane Database Syst Rev. 2005 Oct 19;(4):CD001799 [16235286.001]
  • [Cites] Cancer. 1995 Jan 15;75(2):435-9 [7529127.001]
  • [Cites] Tumori. 2001 Sep-Oct;87(5):299-302 [11765177.001]
  • [Cites] Eur J Cancer. 1997 Jul;33(8):1216-20 [9301445.001]
  • [Cites] J Clin Oncol. 1995 Nov;13(11):2757-63 [7595735.001]
  • [Cites] N Engl J Med. 2002 Jan 17;346(3):210-1 [11797725.001]
  • [Cites] Invest New Drugs. 2002 Feb;20(1):95-9 [12003198.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23 ):2335-42 [15175435.001]
  • [Cites] N Engl J Med. 1997 Jul 17;337(3):161-7 [9219702.001]
  • [Cites] N Engl J Med. 2002 Jan 17;346(3):210-1 [11797726.001]
  • [Cites] Ann Surg Oncol. 2006 Feb;13(2):214-20 [16418887.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1779-84 [8137201.001]
  • [Cites] Oncology. 2003;65(3):211-7 [14657594.001]
  • [Cites] Eur J Cancer. 1990;26(10):1108-9 [2148891.001]
  • [Cites] Onkologie. 2005 Dec;28(12):647-50 [16330888.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2310-7 [15800321.001]
  • [Cites] Ann Oncol. 2002 May;13(5):721-9 [12075740.001]
  • [Cites] Am J Surg. 2003 Jun;185(6):538-43 [12781882.001]
  • [Cites] Semin Oncol. 1995 Jun;22(3 Suppl 6):35-40 [7541155.001]
  • [Cites] Cancer. 1995 May 1;75(9):2197-202 [7712428.001]
  • [Cites] Gastric Cancer. 2006;9(1):14-8 [16557431.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):1928-34 [15041708.001]
  • [Cites] World J Surg. 1987 Aug;11(4):473-7 [3630192.001]
  • [Cites] Br J Surg. 1980 Jun;67(6):381-90 [6155968.001]
  • [Cites] Br J Cancer. 1995 Mar;71(3):587-91 [7533517.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2005 Apr;17(2):81-90 [15830569.001]
  • [Cites] Cancer. 1996 Nov 15;78(10):2070-7 [8918399.001]
  • [Cites] Lancet Oncol. 2005 Sep;6(9):659-68 [16129366.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1612-9 [16575012.001]
  • [Cites] J Clin Oncol. 1992 Feb;10 (2):269-74 [1732428.001]
  • [Cites] Gastric Cancer. 2003;6 Suppl 1:45-9 [12775020.001]
  • [Cites] Jpn J Clin Oncol. 1991 Jun;21(3):176-9 [1942548.001]
  • [Cites] Cochrane Database Syst Rev. 2006 Jul 19;(3):CD001556 [16855972.001]
  • [Cites] Cochrane Database Syst Rev. 2006 Jan 25;(1):CD002092 [16437440.001]
  • [Cites] Gastric Cancer. 2005;8(2):111-6 [15864718.001]
  • [Cites] Ann Oncol. 1994 Sep;5(7):609-16 [7993836.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2241-52 [14657432.001]
  • [Cites] Br J Cancer. 1996 Sep;74(6):980-4 [8826870.001]
  • [Cites] Anticancer Res. 1992 Nov-Dec;12(6B):1983-8 [1295444.001]
  • [Cites] Eur J Surg. 2002;168(11):597-608 [12699095.001]
  • [Cites] Int J Gastrointest Cancer. 2002;32(2-3):115-23 [12794247.001]
  • [Cites] JAMA. 1999 May 5;281(17):1623-7 [10235156.001]
  • [Cites] Cancer. 1996 Oct 15;78(8):1646-50 [8859175.001]
  • [Cites] Acta Oncol. 1999;38(2):255-9 [10227449.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):305-13 [11208820.001]
  • [Cites] N Engl J Med. 2002 Jan 17;346(3):210-1 [11796861.001]
  • [Cites] N Engl J Med. 1992 Jun 11;326(24):1593-8 [1584260.001]
  • [Cites] Cancer. 1999 Mar 15;85(6):1213-7 [10189124.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2006 Nov;18(11):1197-201 [17033441.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):37-41 [8508427.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1727-33 [12049861.001]
  • [Cites] Ann Oncol. 2000 Sep;11(9):1161-4 [11061612.001]
  • [Cites] Cancer J. 2000 Sep-Oct;6(5):316-23 [11079171.001]
  • [Cites] World J Surg. 1999 Mar;23(3):271-5; discussion 275-6 [9933699.001]
  • [Cites] Cancer J. 2003 Jul-Aug;9(4):251-60 [12967135.001]
  • [Cites] Int J Colorectal Dis. 2003 Jul;18(4):330-4 [12774248.001]
  • [Cites] Anticancer Drugs. 2005 Jul;16(6):621-5 [15930889.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] Br J Cancer. 1998 Aug;78(4):511-4 [9716036.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1441-7 [8336183.001]
  • [Cites] Oncology (Williston Park). 2003 Sep;17 (9 Suppl 8):27-31 [14569845.001]
  • [Cites] Br J Cancer. 2005 Jun 20;92(12):2129-33 [15942631.001]
  • [Cites] World J Gastroenterol. 2002 Dec;8(6):1023-8 [12439918.001]
  • [Cites] Oncology (Williston Park). 2004 Dec;18(14 Suppl 14):22-5 [15685830.001]
  • [Cites] Semin Oncol. 1997 Dec;24(6 Suppl 19):S19-77-S19-81 [9427272.001]
  • [Cites] Cancer. 1999 Feb 15;85(4):763-8 [10091752.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):164-70 [8558192.001]
  • [Cites] Cancer. 1996 Jul 1;78(1):30-4 [8646722.001]
  • [Cites] Int J Cancer. 2002 Jun 20;99(6):860-8 [12115489.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):1996-2004 [11956258.001]
  • [Cites] Invest New Drugs. 1990 Aug;8(3):321-4 [2272772.001]
  • [Cites] Semin Oncol. 1997 Dec;24(6 Suppl 19):S19-86-S19-88 [9427274.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5201-6 [17114652.001]
  • [Cites] Br J Surg. 2001 Sep;88(9):1249-57 [11531876.001]
  • [Cites] Eur J Cancer. 1999 Jul;35(7):1059-64 [10533448.001]
  • [Cites] Cancer. 2007 Jan 1;109(1):33-40 [17133415.001]
  • [Cites] Am J Med. 1980 Feb;68(2):259-66 [6153504.001]
  • [Cites] J Vasc Interv Radiol. 2001 Apr;12(4):465-74 [11287534.001]
  • [Cites] Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232 [7612182.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] Lancet. 1994 May 28;343(8909):1309-12 [7910321.001]
  • [Cites] Ann Oncol. 1997 Feb;8(2):163-8 [9093725.001]
  • [Cites] Ann Oncol. 2004 Feb;15(2):230-5 [14760114.001]
  • [Cites] Intern Med. 1999 Nov;38(11):844-8 [10563743.001]
  • [Cites] N Engl J Med. 1998 Dec 31;339(27):1979-84 [9869669.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):261-7 [8996151.001]
  • [Cites] J Clin Oncol. 1999 Oct;17 (10 ):3270-5 [10506629.001]
  • [Cites] Gastrointest Endosc. 2006 Jan;63(1):134-40 [16377330.001]
  • [Cites] Kurume Med J. 1996;43(2):157-63 [8755119.001]
  • [Cites] J Gastrointest Surg. 2005 Jul-Aug;9(6):794-802 [16187480.001]
  • (PMID = 18034590.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Number-of-references] 125
  •  go-up   go-down


7. Honda M, Miura A, Izumi Y, Kato T, Ryotokuji T, Monma K, Fujiwara J, Egashira H, Nemoto T: Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma. Dis Esophagus; 2010 Nov;23(8):641-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma.
  • The chemotherapy regimen currently used for treating esophageal and gastric carcinoma has been either epirubicin, cisplatin, and fluorouracil (5-FU) or docetaxel, cisplatin, and 5-FU.
  • Here, we report the efficacy and toxicity of doxorubicin, cisplatin, and 5-FU for only esophageal squamous cell carcinoma (ESCC).
  • Between January 2000 and October 2008, a total of 41 ESCC patients with a distant metastasis were enrolled.
  • The median survival time was 306 days (95% CI = 74-935) and the 1-year survival rate was 37.6%.
  • Grade 3 neutropenia was seen in seven patients and grade 4 in one patient.
  • This regimen is effective as a first-line therapy for ESCC with distant metastasis.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Copyright the Authors. Journal compilation © 2010, Wiley Periodicals, Inc. and the International Society for Diseases of the Esophagus.
  • (PMID = 20545978.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


8. Lorenzen S, Duyster J, Lersch C, von Delius S, Hennig M, Bredenkamp R, Peschel C, Lordick F: Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial. Br J Cancer; 2005 Jun 20;92(12):2129-33
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial.
  • Capecitabine and docetaxel have single-agent activity in upper gastrointestinal tumours, and have together demonstrated preclinical synergy and a survival benefit in breast cancer, and high response rates in first-line metastatic gastric cancer.
  • This trial assessed the efficacy, safety and feasibility of capecitabine in combination with docetaxel in patients with metastatic oesophageal cancer.
  • In all, 24 patients with advanced disease (17 squamous cell carcinoma and seven adenocarcinoma) received oral capecitabine (1000 mg m(-2) twice daily on days 1-14) plus intravenous docetaxel (75 mg m(-2) on day 1) every 3 weeks as first- (n = 16) or second-line (n = 8) therapy.
  • Patients received a median of four cycles of treatment (range, 0-6).
  • Of the 11 responders (one complete and 10 partial), nine of 16 (56%) received first-line and two of eight (25%) received second-line therapy.
  • The median time to progression was 6.1 months (95% confidence interval (CI), 4.5-7.7 months).
  • Capecitabine plus docetaxel has a manageable adverse event profile and very promising activity in metastatic oesophageal cancer, at least comparable to other doublet regimens.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Esophageal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drug Administration Schedule. Feasibility Studies. Female. Fluorouracil / analogs & derivatives. Humans. Male. Middle Aged. Survival Analysis. Taxoids / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2812-23 [12065558.001]
  • [Cites] Invest New Drugs. 2002 Feb;20(1):95-9 [12003198.001]
  • [Cites] Ann Oncol. 2003 Dec;14(12):1735-43 [14630678.001]
  • [Cites] Br J Cancer. 2004 Mar 22;90(6):1190-7 [15026800.001]
  • [Cites] Ann Oncol. 2004 Jun;15(6):955-9 [15151954.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Jpn J Clin Oncol. 1992 Jun;22(3):172-6 [1518165.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):164-70 [8558192.001]
  • [Cites] Med Oncol. 1996 Jun;13(2):87-93 [9013471.001]
  • [Cites] Eur J Cancer. 1997 Jul;33(8):1216-20 [9301445.001]
  • [Cites] Clin Cancer Res. 1998 Apr;4(4):1013-9 [9563897.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1826-34 [9586897.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1274-81 [9849491.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):485-93 [10080589.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3270-5 [10506629.001]
  • [Cites] J Chronic Dis. 1961 Apr;13:346-53 [13704181.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 15):12-20 [10566606.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1337-45 [10715306.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;45(4):291-7 [10755317.001]
  • [Cites] Invest New Drugs. 2000 Nov;18(4):343-54 [11081570.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2282-92 [11304782.001]
  • [Cites] J Clin Oncol. 2001 Nov 1;19(21):4097-106 [11689577.001]
  • [Cites] Jpn J Clin Oncol. 2001 Sep;31(9):419-23 [11689594.001]
  • [Cites] Br J Cancer. 2003 Aug 18;89(4):630-3 [12915869.001]
  • (PMID = 15942631.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2361804
  •  go-up   go-down


9. Taïeb J, Artru P, Baujat B, Mabro M, Carola E, Maindrault F, Tournigand C, Krulik M, Louvet C, de Gramont A: Optimisation of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5-FU and cisplatin (HLFP regimen) for metastatic oesophageal cancer. Eur J Cancer; 2002 Mar;38(5):661-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimisation of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5-FU and cisplatin (HLFP regimen) for metastatic oesophageal cancer.
  • To improve the efficacy and tolerance of the 5-fluorouracil (5-FU)/cisplatin combination in metastatic esophageal cancer, we designed a new therapeutic schedule, the HLFP regimen.
  • 42 patients with metastatic oesophageal adenocarcinoma (n=10) or squamous cell carcinoma (n=32) were prospectively enrolled in the study.
  • The median progression-free survival and overall survival times were 8 and 12.7 months, respectively.
  • There were no treatment-related deaths.
  • These results suggest that the HLFP regimen is an active and well-tolerated chemotherapy for metastatic oesophageal carcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / secondary. Esophageal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Cisplatin / administration & dosage. Deglutition Disorders / drug therapy. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Male. Middle Aged. Multivariate Analysis. Prospective Studies. Survival Rate. Treatment Outcome. Weight Gain / drug effects

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Cancer. 2002 Mar;38(5):635-8 [11916543.001]
  • (PMID = 11916548.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; HLFP regimen
  •  go-up   go-down


10. Bidoli P, Stani SC, De Candis D, Cortinovis D, Parra HS, Bajetta E: Single-agent chemotherapy with vinorelbine for pretreated or metastatic squamous cell carcinoma of the esophagus. Tumori; 2001 Sep-Oct;87(5):299-302
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-agent chemotherapy with vinorelbine for pretreated or metastatic squamous cell carcinoma of the esophagus.
  • AIMS AND BACKGROUND: At least half of the patients with squamous cell carcinoma of the esophagus (SCCE) present at diagnosis with metastatic disease, and most patients in a locally advanced phase will develop metastases despite potentially curative local therapy.
  • Thus, the majority of patients with SCCE will become candidate for palliative chemotherapy.
  • Only a few drugs have demonstrated moderate activity (>15%) against SCCE.
  • The main purpose of this phase II trial was to assess the activity of vinorelbine, a semisynthetic vinca alkaloid with a wide spectrum of action, in advanced or relapsed SCCE.
  • Eleven of them had already received chemotherapy (cisplatin and fluorouracil) and/or radiotherapy at the time of the first diagnosis.
  • RESULTS: Sixteen of the 17 patients enrolled in the trial were assessable for activity: partial responses were observed in 4 of the 16 (25%), and 3 of them were pre-treated patients.
  • A significant improvement of dysphagia was obtained in 4 of 11 symptomatic patients.
  • The good tolerability and the possibility of relieving symptoms such as dysphagia strongly suggest the addition of vinorelbine to combination regimens with cisplatin as front-line chemotherapy for SCCE.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Esophageal Neoplasms / drug therapy. Vinblastine / analogs & derivatives. Vinblastine / therapeutic use

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11765177.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5V9KLZ54CY / Vinblastine; Q6C979R91Y / vinorelbine
  •  go-up   go-down


11. Lee J, Im YH, Cho EY, Hong YS, Lee HR, Kim HS, Kim MJ, Kim K, Kang WK, Park K, Shim YM: A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. Cancer Chemother Pharmacol; 2008 Jun;62(1):77-84
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma.
  • PURPOSE: The combination of 5-fluorouracil (5-FU) and cisplatin (FP) remains the mostly used regimen for metastatic esophageal squamous carcinoma.
  • This phase II study assessed the efficacy and safety of capecitabine/cisplatin (XP) as a first-line chemotherapy in a homogenous cohort of patients with metastatic or recurrent esophageal squamous cell carcinoma.
  • MATERIALS AND METHODS: Patients received 60 mg/m(2) of cisplatin intravenously (IV) on day 1 and capecitabine 1,250 mg/m(2)/dose orally twice a day on days 1-14.
  • Treatment cycles were repeated every 3 weeks until the documented disease progression, unacceptable toxicity, or patient's refusal.
  • Immunohistochemical studies against thymidylate synthase (TS) and thymidine phosphorylase (TP) were performed to seek predictive markers for treatment response.
  • All patients had histologically proven squamous cell carcinoma of the esophagus.
  • With a median follow-up duration of 25.7 months (10.8-42.6 months), the median time to progression was 4.7 months (95% CI, 2.5-7.0) and the median survival time was 11.2 months (95% CI, 8.5-13.9).
  • Common grade 3 or 4 non-hematological adverse events were anorexia (18/191, 9.4%), fatigue (9/191, 4.7%), constipation (6/191, 3.1%), hand-foot syndrome (6/191, 3.1%) and diarrhea (4/191, 2.1%).
  • There was no treatment-related death.
  • Neither TS nor TP showed predictive value for treatment response.
  • CONCLUSION: The XP regimen demonstrated a promising antitumor activity in metastatic esophageal squamous cell carcinoma, which may potentially replace the FP regimen.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Esophageal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17762932.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; EC 2.1.1.45 / Thymidylate Synthase; EC 2.4.2.4 / Thymidine Phosphorylase; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


12. Conroy T, Etienne PL, Adenis A, Ducreux M, Paillot B, Oliveira J, Seitz JF, Francois E, Van Cutsem E, Wagener DJ, Kohser F, Daamen S, Praet M, Gorlia T, Baron B, Wils J, European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group: Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival. Ann Oncol; 2002 May;13(5):721-9
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival.
  • BACKGROUND: Vinorelbine and cisplatin are active against squamous cell oesophageal carcinoma.
  • The purpose of this phase II study was to evaluate the efficacy and safety of vinorelbine plus cisplatin in previously untreated patients with metastatic squamous cell oesophageal carcinoma and to estimate the progression-free survival, overall survival and quality of life (QoL) of the patient population.
  • Toxicity was mainly related to neutropenia (grade 3/4 in 41% of patients).
  • CONCLUSIONS: Vinorelbine plus cisplatin represents a well-tolerated active palliative regimen for patients with advanced squamous cell carcinoma of the oesophagus.
  • This combination may offer a better therapeutic index than cisplatin-5-fluorouracil.


13. Takeshima H, Kuratsu J, Nishi T, Soyama N, Miura M, Masumitsu T, Ushio Y: Metastatic brain tumours from oesophageal carcinoma: neuro-imaging and clinicopathological characteristics in Japanese patients. Acta Neurochir (Wien); 2001;143(1):31-5; discussion 35-6
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic brain tumours from oesophageal carcinoma: neuro-imaging and clinicopathological characteristics in Japanese patients.
  • BACKGROUND: Since metastatic brain tumours from esophageal carcinoma are essentially rare, previous reports have not determined the common neuro-radiological findings and its clinical aspects.
  • FINDINGS: We report the neuro-imaging and clinicopathological features of our 8 metastatic brain tumours from an esophageal site.
  • Histologically, 6 of our 8 patients had squamous cell carcinoma and 2 had small cell carcinoma, a rare variant form.
  • Both histological types mainly exhibited cystic lesions with a thin enhanced rim on magnetic resonance images (MRI, 4 of 6 squamous cell carcinomas and 1 of 2 small cell carcinomas).
  • Combination therapy (irradiation and chemotherapy) after surgical treatment, the number of metastatic brain tumours, and the interval between their appearance and the diagnosis of the primary lesion could be prognostic factors in our series.
  • INTERPRETATION: Among Japanese, the vast majority of primary esophageal cancers are squamous cell carcinomas.
  • Therefore, MRI findings of a cystic tumour with a thin enhanced rim may alert one to the possibility of a metastatic brain tumour from the esophagus.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma, Small Cell / secondary. Carcinoma, Squamous Cell / secondary. Esophageal Neoplasms / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Brain / pathology. Esophagus / pathology. Humans. Japan. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11345715.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


14. Wang Y, Liu D, Chang B, Kao R, Lai Y, Hsu W: A comparison between treatment outcomes of stage III and stage IV esophageal squamous cell carcinoma without visceral or bone metastases. J Clin Oncol; 2009 May 20;27(15_suppl):e15659

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison between treatment outcomes of stage III and stage IV esophageal squamous cell carcinoma without visceral or bone metastases.
  • : e15659 Background: Although classified as end-stage, patients of stage IV esophageal squamous cell carcinoma (SCC) without visceral or bone metastases (nodal stage IV) often have good performance status and are medically fit for curative treatment.
  • The objective of this study was to compare the prognosis of patients of stage III and nodal stage IV.
  • METHODS: The retrospective study included patients who were diagnosed esophageal squamous cell carcinoma at Tzu Chi General Hospital from Jan, 2005 to Aug, 2008.
  • (1) stage III or nodal stage IV;.
  • The standard order-set of chemotherapy was two monthly cycles of fluorouracil (1,000 mg/m2/24 hours for 4 days) and cisplatin (75 mg/m2 bolus day 1).
  • Radiotherapy dose was 59.4 Gy for concurrent chemoradiation (CCRT) or 54 Gy for adjuvant setting after esophagectomy.
  • In 38 patients underwent definitive CCRT, ten achieved complete response (CR) and 13 achieved partial response.
  • Median survival of stage III and nodal IV were 11.5 and 8 months.
  • Two-year overall survival (OS) rate of stage III and nodal IV were 23.9% and 33% (p=0.814).
  • CONCLUSIONS: In our study, medically fit patients of nodal stage IV esophageal SCC could achieve OS similar to those of stage III after intensive treatment.
  • The result may indicate the necessity of developing a selection criterion in deciding which nodal stage IV patient should undergo curative treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962775.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Lin CC, Yeh KH, Yang CH, Hsu C, Tsai YC, Hsu WL, Cheng AL, Hsu CH: Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma. Anticancer Drugs; 2007 Jul;18(6):703-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma.
  • This study assessed the clinical activity and safety of twice-weekly paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin (TP-HDFL) in patients with recurrent or metastatic esophageal squamous cell carcinoma.
  • Forty-one patients (median age 51), 15 with de-novo metastatic disease and 26 with recurrent disease, were enrolled.
  • Twice-weekly TP-HDFL has the activity and toxicity profile similar to the previously reported same three-drug combination for advanced esophageal cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Esophageal Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cisplatin / therapeutic use. Disease-Free Survival. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Fluorouracil / therapeutic use. Humans. Infusions, Intravenous. Leucovorin / administration & dosage. Leucovorin / adverse effects. Leucovorin / therapeutic use. Male. Middle Aged. Neoplasm Metastasis. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Paclitaxel / therapeutic use

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17762400.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


16. Tanaka K, Mohri Y, Ohi M, Yokoe T, Koike Y, Morimoto Y, Miki C, Tonouchi H, Kusunoki M: Mitotic checkpoint genes, hsMAD2 and BubR1, in oesophageal squamous cancer cells and their association with 5-fluorouracil and cisplatin-based radiochemotherapy. Clin Oncol (R Coll Radiol); 2008 Oct;20(8):639-46
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitotic checkpoint genes, hsMAD2 and BubR1, in oesophageal squamous cancer cells and their association with 5-fluorouracil and cisplatin-based radiochemotherapy.
  • AIMS: HsMAD2 and BubR1 are crucial components of a functional mitotic checkpoint.
  • Recently, impaired mitotic checkpoints or decreased expression of mitotic checkpoint genes have been associated with sensitivity to certain anticancer drugs.
  • The current study aimed to evaluate the association of hsMAD2 and BubR1 with sensitivity to various anticancer drugs in oesophageal squamous cell carcinoma (ESCC) cell lines.
  • MATERIALS AND METHODS: HsMAD2 and BubR1 mRNA levels in six ESCC cell lines and 21 ESCC patients were determined by real-time reverse transcription polymerase chain reaction.
  • Responses to 5-fluorouracil, cisplatin, paclitaxel and docetaxel in human oesophageal cancer cell lines, TE1 and TE2, were evaluated by WST-8 colorimetric assay.
  • HsMAD2 and BubR1 were significantly higher in cancer tissue than in adjacent normal tissue (P < 0.01).
  • There was a significantly strong positive association between hsMAD2 and BubR1 in cancer tissue (P < 0.01).
  • Decreased hsMAD2 and BubR1 after radiochemotherapy may indicate the potential efficacy of taxanes as second-line chemotherapy for recurrent and metastatic oesophageal cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Calcium-Binding Proteins / genetics. Carcinoma, Squamous Cell / genetics. Cell Cycle Proteins / genetics. Cisplatin / administration & dosage. Esophageal Neoplasms / genetics. Fluorouracil / administration & dosage. Protein-Serine-Threonine Kinases / genetics. Repressor Proteins / genetics
  • [MeSH-minor] Aged. Aged, 80 and over. Cell Line, Tumor. Combined Modality Therapy. Female. Gene Expression. Humans. Mad2 Proteins. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18691855.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / Cell Cycle Proteins; 0 / MAD2L1 protein, human; 0 / Mad2 Proteins; 0 / Repressor Proteins; EC 2.7.11.1 / BUB1 protein, human; EC 2.7.11.1 / Bub1 spindle checkpoint protein; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


17. Wolff K, Wein A, Reulbach U, Männlein G, Brückl V, Meier C, Ostermeier N, Schwab SA, Horbach T, Hohenberger W, Hahn EG, Boxberger F: Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial. Anticancer Drugs; 2009 Mar;20(3):165-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial.
  • In the majority of patients with oesophageal carcinoma, curative treatment proves to be impossible when diagnosis was established; therefore, most of the patients are candidates for palliative chemotherapy.
  • The aim of this phase II study was to evaluate the efficacy and safety of 5-fluorouracil/folinic acid (AIO regimen) plus irinotecan in patients with locally advanced or metastatic carcinoma of the oesophagus.
  • The methods used a prospective phase II trial, start: November 2002; patients: n=25; chemotherapy: irinotecan (80 mg/m2) as a 1-h infusion and 5-fluorouracil (2000 mg/m2) with sodium folinic acid (500 mg/m2) as a 24-h infusion on days 1, 8, 15, 22, 29 and 36, repeated on day 57.
  • Last date of evaluation: 28 February 2007; n=24; adenocarcinoma: n=13, squamous cell carcinoma (SCC): n=11; UICC III/IV: 3/21; grading G1/G2/G3/G4: 0/8/12/4; median age: 58 years (range 44-75); men/women: 19/5; Eastern Cooperative Oncology Group index 0/1/2: 3/17/4; applications: 460.
  • Time-to-progression: 6.6 months (range 1.6-24.6).
  • In oesophageal carcinomas, the AIO regimen plus irinotecan is excellently manageable as an outpatient treatment and shows efficacy in adenocarcinomas and SCCs of the oesophagus.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Esophageal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Kaplan-Meier Estimate. Leucovorin / administration & dosage. Leucovorin / adverse effects. Male. Middle Aged. Palliative Care. Prospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19125117.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


18. Kroep JR, Pinedo HM, Giaccone G, Van Bochove A, Peters GJ, Van Groeningen CJ: Phase II study of cisplatin preceding gemcitabine in patients with advanced oesophageal cancer. Ann Oncol; 2004 Feb;15(2):230-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of cisplatin preceding gemcitabine in patients with advanced oesophageal cancer.
  • BACKGROUND: For oesophageal cancer there is no effective standard therapy.
  • We studied the feasibility and efficacy of the cisplatin-gemcitabine combination chemotherapy in patients with unresectable oesophageal cancer.
  • PATIENTS AND METHODS: Thirty-six chemonaïve patients with unresectable or metastatic oesophageal adenocarcinoma (24) or squamous-cell-carcinoma (12) were treated with cisplatin (50 mg/m2, days 1 and 8), followed by gemcitabine (800 mg/m2, days 2, 9 and 16), every 28 days.
  • A median number of four therapy cycles was given.
  • Three patients developed neutropenic fever.
  • Anaemia required treatment with erythropoietin, red blood cells or both in 81% of patients.
  • Non-haematological toxicity consisted mainly of grade 1/2 nausea/vomiting or fatigue.
  • CONCLUSION: This cisplatin-gemcitabine regimen was feasible, with myelosupression being the main toxicity, and had significant activity in patients with advanced oesophageal cancer.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14760114.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


19. Assersohn L, Brown G, Cunningham D, Ward C, Oates J, Waters JS, Hill ME, Norman AR: Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol; 2004 Jan;15(1):64-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma.
  • BACKGROUND: The purpose of this study was to assess the efficacy and toxicity of irinotecan and 5-fluorouracil (5-FU) in primary refractory or relapsed locally advanced or metastatic oesophagogastric (O-G) carcinoma.
  • PATIENTS AND METHODS: Patients with documented progression on or within 3 months of chemotherapy were recruited between July 2000 and May 2002.
  • Response confirmed by computed tomography was assessed at 12 and 24 weeks.
  • Thirty-three patients (86.8%) had metastatic disease and 37 patients (97.4%) had previously received platinum-based chemotherapy.
  • CONCLUSION: 5-FU/irinotecan is a valuable regimen for second-line treatment in 5-FU/platinum-resistant O-G carcinoma.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14679122.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


20. Conroy T: Activity of vinorelbine in gastrointestinal cancers. Crit Rev Oncol Hematol; 2002 May;42(2):173-8
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two phase II studies in metastatic colorectal cancer resulted in conflicting results: no activity in first-line therapy on lung metastases, but encouraging results in 5-fluorouracil (5-FU)-resistant metastases.
  • Conversely, significant antitumoural effect in oesophageal squamous cell carcinoma has been demonstrated.
  • The first study was performed in 46 patients with metastatic disease.
  • Six of 30 patients (20%) without prior chemotherapy achieved a partial response (95% confidence interval (CI), 8-39%).
  • One of 16 (6%) with prior chemotherapy responded.
  • A phase I study was performed using VNR and concurrent radiation (64 Gy) in previously untreated patients with inoperable locally advanced oesophageal cancer ineligible for cisplatin-5-FU-based chemoradiation.
  • A phase II study of a VNR-cisplatin combination in metastatic oesophageal squamous cell carcinoma was recently completed.
  • The response rate was 37% (95% CI, 26-49%) with a median duration of response of 7.7 months.
  • [MeSH-major] Gastrointestinal Neoplasms / drug therapy. Vinblastine / analogs & derivatives. Vinblastine / pharmacokinetics
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / pharmacokinetics. Antineoplastic Agents, Phytogenic / toxicity. Clinical Trials as Topic. Humans. Treatment Outcome

  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12007975.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5V9KLZ54CY / Vinblastine; Q6C979R91Y / vinorelbine
  • [Number-of-references] 28
  •  go-up   go-down


21. Polee MB, Verweij J, Siersema PD, Tilanus HW, Splinter TA, Stoter G, Van der Gaast A: Phase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced oesophageal cancer. Eur J Cancer; 2002 Jul;38(11):1495-500
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced oesophageal cancer.
  • The objective of this study was to determine the toxicities and maximum tolerated dose (MTD) of a dose-dense schedule with a fixed dose of cisplatin and escalating doses of paclitaxel in patients with metastatic or irresectable squamous cell-, adeno-, or undifferentiated carcinoma of the oesophagus.
  • Patients received paclitaxel over 3 h followed by a 3-h infusion of a fixed dose of cisplatin of 70 mg/m(2) on days 1, 8, 15, 29, 36 and 43.
  • Patients were re-treated if white blood cell count (WBC) was >/=1 x 10(9) cells/l, except for day 29 when the WBC had to be >/=3 x 10(9) cells/l.
  • Of the 24 patients enrolled, 13 had adenocarcinoma, 10 had squamous cell carcinoma and one had an undifferentiated carcinoma.
  • At this dose, 3 out of 6 patients developed dose-limiting toxicity (DLT) including neutropenic enterocolitis with sepsis, vomiting and diarrhoea.
  • Diarrhoea grades 3 and 4 was seen in 4 (17%) patients.
  • Of the 22 evaluable patients, 11 (50%) patients achieved a partial or complete response with a median duration of 13 months.
  • Ten patients with either locally advanced disease or supraclavicular or celiac lymph nodes received additional local treatment after response to chemotherapy, seven patients are still without evidence of disease after a median follow-up of 32 months.
  • Paclitaxel at a dose 100 mg/m(2) infused over 3 h followed by a 3-h infusion of 70 mg/m(2) cisplatin can be recommended for further studies in patients with metastatic or unresectable oesophageal cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carcinoma, Squamous Cell / drug therapy. Cisplatin / adverse effects. Esophageal Neoplasms / drug therapy. Paclitaxel / adverse effects
  • [MeSH-minor] Adult. Aged. Diarrhea / chemically induced. Dose-Response Relationship, Drug. Female. Hematologic Diseases / chemically induced. Humans. Infusions, Intravenous. Male. Maximum Tolerated Dose. Middle Aged. Nervous System Diseases / chemically induced. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12110496.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


22. Zieliński M, Hauer L, Hauer J, Nabiałek T, Szlubowski A, Pankowski J: Non-small-cell lung cancer restaging with transcervical extended mediastinal lymphadenectomy. Eur J Cardiothorac Surg; 2010 Apr;37(4):776-80
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-small-cell lung cancer restaging with transcervical extended mediastinal lymphadenectomy.
  • BACKGROUND: To analyse a diagnostic yield of the transcervical extended mediastinal lymphadenectomy (TEMLA) in restaging of the mediastinal nodes after neoadjuvant chemo- or chemo-radiotherapy for non-small-cell lung cancer (NSCLC).
  • METHODS: From 1 January 2004 to 30 April 2009, 63 patients who underwent induction chemotherapy or chemo-radiotherapy for N2 and N2/3 metastatic nodes discovered preoperatively were restaged.
  • There were 45 squamous cell carcinomas, 13 adenocarcinomas, one pleomorphic carcinoma and four NSCLCs.
  • A total of 54 patients underwent neoadjuvant chemotherapy and nine chemo-radiotherapy.
  • Seven patients had mediastinoscopy before neoadjuvant therapy.
  • As many as 34 patients underwent endobronchial ultrasound (EBUS), one patient underwent endo-oesophageal ultrasound (EUS) and 10 patients underwent combined EBUS/EUS.
  • Metastatic nodes were discovered in 22 patients including three patients with N3 nodes and 19 patients with N2 nodes.
  • There was no postoperative mortality, two bronchial fistulas were developed (after inferior bilobectomy and right pneumonectomy; the second one healed spontaneously) and there were no other serious complications.
  • During follow-up a local recurrence was noted in six of 37 (15.7%) patients after pulmonary resection. CONCLUSIONS:.
  • (1) The results of TEMLA in restaging of NSCLC (N2/3) patients after induction chemotherapy or chemo-radiotherapy were significantly better than those achieved with remediastinoscopy, EBUS and positron emission tomography/computed tomography (PET/CT). (2) The results of future studies will show if TEMLA should be considered the gold standard of mediastinal nodal restaging after neoadjuvant therapy in patients with NSCLC.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Epidemiologic Methods. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Mediastinoscopy. Mediastinum. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Radiotherapy, Adjuvant. Thoracotomy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
  • [CommentIn] Eur J Cardiothorac Surg. 2010 Apr;37(4):780-1 [20036137.001]
  • (PMID = 20044265.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


23. Cho SH, Shim HJ, Lee SR, Ahn JS, Yang DH, Kim YK, Nam TK, Lee JJ, Kim HJ, Chung IJ: Concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer. Dis Esophagus; 2008;21(8):697-703
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer.
  • How best to manage advanced esophageal cancer remains unresolved, especially in palliative care.
  • Here, in a pilot study, we evaluated the efficacy and safety of concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer.
  • Patients with locally advanced or metastatic squamous cell carcinoma of the esophagus received S-1 and cisplatin at doses of 70 mg/m(2)/day for 14 days and 70 mg/m(2) on day 1, respectively, every 3 weeks.
  • After concurrent chemoradiotherapy, additive chemotherapy was repeated up to six cycles.
  • In patients with stage II or III esophageal cancer, the median progression-free survival and overall survival were 10.6 +/- 0.6 months (95% CI: 9.4-11.8) and 23.0 +/- 5.1 months (95% CI: 13.0-32.9), respectively.
  • In patients with stage IV esophageal cancer, the median progression-free survival and overall survival were 5.4 +/- 1.6 months (95% CI: 2.2-8.6) and 11.6 +/- 1.6 months (95% CI: 8.4-14.8), respectively.
  • The major non-hematological toxicities were asthenia and vomiting, mostly of grades 1 and 2.
  • Thus, concurrent chemoradiotherapy with S-1 and cisplatin may be a promising nonsurgical treatment in advanced esophageal cancer.

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18522639.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


24. Lorenzen S, Schuster T, Porschen R, Al-Batran SE, Hofheinz R, Thuss-Patience P, Moehler M, Grabowski P, Arnold D, Greten T, Müller L, Röthling N, Peschel C, Langer R, Lordick F: Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol; 2009 Oct;20(10):1667-73
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie.
  • BACKGROUND: This study assessed the activity of the mAb cetuximab in combination with cisplatin and 5-fluorouracil (5-FU) in advanced esophageal squamous cell carcinoma.
  • With a median follow-up of 21.5 months, the median progression-free survival was 5.9 and 3.6 months and median overall survival 9.5 and 5.5 months for CET-CF and CF, respectively.
  • CONCLUSION: Cetuximab can be safely combined with CF chemotherapy and may increase the efficacy of standard CF chemotherapy.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19549707.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; PQX0D8J21J / Cetuximab; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


25. Zhang X, Shen L, Li J, Li Y, Li J, Jin M: A phase II trial of paclitaxel and cisplatin in patients with advanced squamous-cell carcinoma of the esophagus. Am J Clin Oncol; 2008 Feb;31(1):29-33
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of paclitaxel and cisplatin in patients with advanced squamous-cell carcinoma of the esophagus.
  • OBJECTIVE: To evaluate the response rate, survival, and toxicities of paclitaxel plus cisplatin combination in patients with advanced or metastatic squamous-cell carcinoma of the esophagus.
  • METHODS: Thirty-nine patients with definite measurable indices and no prior chemotherapy were enrolled.
  • Treatment was repeated every 21 days.
  • The median time to progression was 7 months, and median survival time of all patients was 13 months.
  • No grade 4 toxicities and treatment-related deaths were recorded in all patients.
  • CONCLUSION: Paclitaxel and cisplatin is a promising treatment for patients with squamous-cell carcinoma of the esophagus.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Esophageal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Female. Follow-Up Studies. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Paclitaxel / administration & dosage. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18376224.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down






Advertisement